GENE - The Buzz Show: OpGen Inc. (NASDAQ: OPGN) FDA Clearance for Acuitas® AMR Gene Panel

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “OpGen, Inc. Receives FDA Clearance for Acuitas® AMR Gene Panel”

OpGen, Inc. (NASDAQ: OPGN) surged over 25% in premarket trading after the company received the 510(k) clearance by the U.S. FDA to market the Acuitas® AMR Gene Panel

The Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogens and the company is targeting the fourth quarter for its commercial launch later this year.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

For more information, please visit: OpGen, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: OpGen, Inc. (NASDAQ: OPGN) FDA Clearance for Acuitas® AMR Gene Panel first appeared on Financial Buzz .

For further details see: